Stem cell transplantation therapy for advanced liver damage-associated neurodegenerative disorders Authors: Anjna Sharma, Ameya Sharma, Divya Dheer, Raghu Rai Sharma, Vivek Puri, Shabana Bibi, Amina Shamas, Sameeullah Memon, Rajat Goyal, Priyanka, Hitesh Chopra Published: 2024 ABSTRACT AbstractHepatic encephalopathy and other neurodegenerative disorders have profound implications for extensive liver impairment, calling for new ways of treating the condition. The application of stem cell transplantation to treat these severe disorders is a new and encouraging technique. This review article digs deep into the subject of stem cell transplantation therapy, neurodegenerative disorders associated with advanced liver damage, and liver transplantation. It comprehensively analyses the background, rationale, scope, and objectives of using stem cells to treat such challenging conditions. The topic of discussion includes the subtleties of neurodegenerative disorders, the function of liver transplantation, and the possible advantages and disadvantages associated with it. The relevance of patient selection, intraoperative concerns and post-transplant care is discussed. Further, the article explores how stem cell-based therapies can benefit from nanotechnology, specifically how it can improve stem cell distribution, survival, and integration for better therapeutic results. This review aims to offer a thorough analysis of regenerative medicine’s present and future possibilities in dealing with the intricate relationship between neurodegeneration and liver damage. It does this by examining the efficacy, safety, and long-term impacts of stem cell transplantation in treating neurodegenerative disorders associated with advanced liver damage. This will incorporate insights from ongoing clinical trials, the patent landscape, and future directions. The goal is to pave the way for innovative and personalized treatment approaches in this evolving research and clinical practice field. Therefore, these efforts represent a promising frontier in medical research that can alleviate the burden of HE and associated neurological complications combined with liver cirrhosis.Keywords: Liver, Cancer, transplantation, nanotechnology, stem cell, clinical trials, patents Introduction Highlights Discusses the types of neurodegenerative disorders and its complications. Discusses the types of neurodegenerative disorders and its complications. Understanding the significance of liver transplantation in neurodegenerative disorders. Understanding the significance of liver transplantation in neurodegenerative disorders. Discusses the subtleties of liver transplantation, potential advantages and disadvantages. Discusses the subtleties of liver transplantation, potential advantages and disadvantages. Explores the treatment aspects and challenges of nanotechnology and stem cell therapy implemented in liver transplantation. Explores the treatment aspects and challenges of nanotechnology and stem cell therapy implemented in liver transplantation. Explores the clinical data and IPR available on the treatment methodology. Explores the clinical data and IPR available on the treatment methodology. Liver cirrhosis is a leading cause of morbidity and death in patients with advanced liver damage and can progress to hepatocellular carcinoma (HCC) and hepatic decompensation, including hepatic encephalopathy1. Liver cirrhosis was responsible for 2.4% of all fatalities in 2019 and is one of the leading causes of mortality globally2. Hepatic encephalopathy (HE) is a neuropsychiatric illness characterized by a high frequency and recurrence rate, as well as fatal metabolic complications caused by advanced liver disease3,4. HE affects up to 40% of people with cirrhosis5. Clinically, HE is distinguished by hyperammonemia, EEG abnormalities, and varying degrees of sensory, motor, and cognitive dysfunction4. Neurotoxic ammonia, as well as systemic and neurological inflammation, are thought to be the primary causes of this neuropsychiatric disease6. HE may interfere with daily activities, lowering work performance and quality of life. It can raise the risk of accidents and impair the prognosis for people with advanced liver disease7. The molecular mechanism of HE has not been fully explored. However, it is widely believed that HE is caused by various variables, including the synergistic combination of toxin buildup and severe metabolic disruption3. Ammonia poisoning and the resulting oxidative/nitrosative stress remain the dominant ideas, and lowering blood ammonia is thus the primary method for treating HE8. Other pathogenic processes include manganese toxicity, autophagy suppression, mitochondrial damage, inflammation, and aging4. The diagnosis is often determined by considering the presence of suggestive and compatible clinical symptoms, a predisposing hepatic disease, and the exclusion of other causes with comparable clinical signs9,10. There are no suitable and effective curative treatments for these disorders; only palliative and symptomatic medicines are available, and the discovery of innovative medications is impeded by HE’s complexity and heterogeneity6. The lack of medicinal therapies for HE disease has a significant economic impact and hardship on society11. Pharmacotherapies and surgical techniques, such as deep brain stimulation, are administered to patients. However, they are only helpful for symptoms, not illnesses12. The only effective treatment for liver failure and its related problems, such as HE, was liver transplantation (LT), which has been proven to improve well-being, longevity, and cognitive performance significantly13 Nowadays, stem cell-based therapy offers a potential new approach to dealing with liver damage and associated HE14. In animal models and people with HE diseases, stem cell transplantation can speed healing by supplying trophic factors that promote the survival and recovery of host hepatocytes and neurons15. Several methods may contribute to favourable therapeutic outcomes, including cell replacement, cell combination, neurotrophic factor release, endogenous stem cell proliferation, and differentiation16. With the recent breakthroughs in stem cell treatments, a new hope for a cure has emerged because they can cure the same12. Nanotechnology offers enormous potential for the delivery, monitoring, and effectiveness of stem cell therapy. Nanoparticles can encapsulate stem cells to protect them from degeneration17. Stem cell treatments can work more effectively and sustainably, supporting tissue regeneration by acting as substrates or scaffolds and providing structural support. This paper discusses contemporary research and development of stem cell treatment for HE. This review summarizes current developments in stem cell therapy for advanced liver disease-related neurodegeneration and updates in the area. Neurodegenerative disorder and liver transplantation Understanding neurodegenerative disorder Neurodegeneration (ND) is a continuous process of loss or dysfunctions of neurons or neuronal cells of the brain18,19. Clinical symptoms of body rigidity, tremors, psychological changes, depression, loss of memory and frequent tremors mainly characterize it. Other pathological diseased states of the body, such as hepatic encephalopathy, can lead to neurodegeneration due to dysfunction and failure of normal liver functions as a result of infection, injury or trauma requiring liver transplantation (LT)20. Neurodegeneration in these conditions was evaluated by analyzing diffusion tensor imaging (DTI) data and cytotoxic and vasogenic invasion. The white matter of fatty liver disease (FLD) patients shows increased fast mean diffusivity and decreased Fractional anisotropy (FA), normalizing post-liver transplantations21. Damage to brain physiology often arises due to decreased FA in post-transplantation, leading to microstructural damage22. Several neurological concerns following LT can also arise due to surgical invasion, therapies designed against immunity, metabolic disturbances and pre-existing diseases, as represented in Figure 1: Encephalopathy: Metabolic factors, including electrolyte disturbances and hepatic encephalopathy, cause an encephalopathy transplantation-like situation that can lead to immediate death in some circumstances. Occurrence of liver dysfunction leads to impaired cognition and other severe neuronal conditions23. Encephalopathy: Metabolic factors, including electrolyte disturbances and hepatic encephalopathy, cause an encephalopathy transplantation-like situation that can lead to immediate death in some circumstances. Occurrence of liver dysfunction leads to impaired cognition and other severe neuronal conditions23. Neurotoxicity: LT patients need medication like immunosuppressant drugs such as Tacrolimus, cyclosporine and steroids that intricate the neurotoxic pathways. Immunosuppressive agents are solely responsible for side effects such as kindling, posterior reversible encephalopathy syndrome and other cognitive disorders. Ischaemic haemorrhagic strokes are also seen in these patients. Secondarily, Immunosuppressant use can also result in thromboembolism in some of the patients24–26. Neurotoxicity: LT patients need medication like immunosuppressant drugs such as Tacrolimus, cyclosporine and steroids that intricate the neurotoxic pathways. Immunosuppressive agents are solely responsible for side effects such as kindling, posterior reversible encephalopathy syndrome and other cognitive disorders. Ischaemic haemorrhagic strokes are also seen in these patients. Secondarily, Immunosuppressant use can also result in thromboembolism in some of the patients24–26. Infectious diseases: The various viral infections due to infective agents such as cytomegalovirus (CMV), Herpes simplex virus and cryptococcal meningitis may happen following liver transplantation27,28. Infectious diseases: The various viral infections due to infective agents such as cytomegalovirus (CMV), Herpes simplex virus and cryptococcal meningitis may happen following liver transplantation27,28. Neuropathic invasion: Neuropathies, likely axonal neuropathy, and demyelinating neuronal disease have been seen in postoperative LT patients. These patients also develop metabolic derangements, decreased nutritional values and polyneuropathic conditions29,30. Neuropathic invasion: Neuropathies, likely axonal neuropathy, and demyelinating neuronal disease have been seen in postoperative LT patients. These patients also develop metabolic derangements, decreased nutritional values and polyneuropathic conditions29,30. Graft invasion: Categories of graft rejection include acute and chronic rejection due to neurological factors, which can change mental status, tremors or deficit due to vasculopathy. The worst-case scenario of graft rejection includes severe allergic reactions, which ultimately impact the overall quality of life of a patient31. Graft invasion: Categories of graft rejection include acute and chronic rejection due to neurological factors, which can change mental status, tremors or deficit due to vasculopathy. The worst-case scenario of graft rejection includes severe allergic reactions, which ultimately impact the overall quality of life of a patient31. Postoperative neurological diseases: Neurological concerns following LT include delirium, hallucination due to anaesthesia and postoperative care. These concerns manifest uncertainty in individuals, altered awareness and lack of cognition ability. The risk factors for these concerns involve age, pre-existing neuronal diseases and prolonged invasive surgeries32,33. Postoperative neurological diseases: Neurological concerns following LT include delirium, hallucination due to anaesthesia and postoperative care. These concerns manifest uncertainty in individuals, altered awareness and lack of cognition ability. The risk factors for these concerns involve age, pre-existing neuronal diseases and prolonged invasive surgeries32,33. Neurological complications in liver transplant recipients. Indications for liver transplantation in neurodegenerative disorder Cognitive disorders like Wilson disease, where individuals experience a majority of abnormal neural symptoms, are considered a significant consequence of liver transplantations34. For the management of irreversible mental disorders, LT can be an alternative treatment option. However, international guidelines do not recommend LT as a standard treatment due to the risk of infection and rejection or failure of surgery. Patients may also develop severe neurological complications even after surgical operations (~30%)35,36. The underlying mechanism of LT involves the treatment of neuro-psychic disorders by maintaining metabolic homoeostasis and balance in neurotransmitters. LT can also hold therapeutic benefits for affected people in improving long-term neurological conditions37,38. Efficacy of liver transplantation in neurodegenerative disorders According to some individuals, liver transplantation can change the body’s metabolic environment, making it a possible treatment for several neurological diseases. Specifically, liver transplantation has demonstrated encouraging outcomes in the treatment of Wilson’s disease and familial amyloid polyneuropathy39,40. Improvements in specific symptoms and biochemical markers linked with neurological disorders have been shown in clinical outcomes after liver transplantation. As an example, liver transplantation can alleviate neurological symptoms associated with Wilson’s disease by reducing the accumulation of copper in the brain, which is triggered by a malfunction in copper metabolism. The specific problem and the stage of the disease determine the long-term prognosis after liver transplantation for neurological diseases41–44. Patients with some diseases, such as familial amyloid polyneuropathy, may find that liver transplantation helps to alleviate symptoms and slow down the course of their disease45. There is continuing discussion and investigation into how liver transplantation affects the development of neurodegenerative diseases. More research is necessary to understand the mechanisms behind the effects of liver transplantation on neurological deterioration and to find the best way to treat neurodegenerative disorders. However, some studies have shown that it can sometimes stop or slow the process. Nanotechnology and stem cell-based therapy Recent advances in nanotechnology have generated great hopes in biology and medicine, with many experts predicting that this new technology would answer long-standing mysteries about the microscopic dynamics of living systems46,47 Nanomedicine, which entails applying nanoscale science and engineering to biological problems, has recently garnered much interest from nanotech researchers48–50. Intrinsic, very specialized interactions between biological systems, nanostructures, and nanomaterials can occur at the single-molecule level51. The unique characteristics of nanomaterials and nanostructures can be invaluable when it comes to understanding how stem cells behave in embryos and adults and manipulating intrinsic stem cell signals (Fig. 2). Nanotechnology in stem cell-based therapy. A critical role for nanotechnology in stem cell studies and treatment The field of stem cell research and therapy has been profoundly affected by nanotechnology, which involves manipulating and fabricating materials and devices on the scale of nanometres. Innovative techniques for cell isolation, purification, differentiation, and therapeutic applications have been made possible by its incorporation with stem cell research, which has expanded possibilities for improvements in regenerative medicine. Improving stem cell separation and purification Isolating and purifying stem cells from biological sources is a crucial first step in treatment. Materials and machines made possible by nanotechnology have increased the specificity and efficiency of such procedures. Isolating and sorting stem cells has been accomplished with the use of magnetic nanoparticles (MNPs), which use their magnetic characteristics to sort stem cells from heterogeneous cell mixtures52. Supporting the differentiation of stem cells Regenerative medicine relies on the capacity to control the development of stem cells into specific cell types. Researchers have used nanomaterials like quantum dots and carbon nanotubes (CNTs) to manipulate stem cell development. These materials can deliver chemical and physical signals that mirror the cellular environment, encouraging stem cell differentiation into target lineages53. Enhancing imaging and tracking of stem cells To determine if stem cell treatments are effective, tracking what happens to the cells after transplantation is crucial. Using fluorescent nanoparticles to monitor and observe stem cells in vivo is one example of how nanotechnology has aided the creation of new imaging methods. The distribution, engraftment, and differentiation of stem cells may be monitored in real-time using these designed nanoparticles that produce signals detectable by different imaging modalities54,55. The next step in stem cell engineering and delivery Significant obstacles in stem cell treatment include transporting and engrafting stem cells into specific organs. One potential use of nanotechnology is the development of nanoscale carriers and scaffolds, which can improve the transplanted stem cells’ chances of survival, localization, and integration. Nanofiber scaffolds can provide a supporting matrix that imitates the extracellular matrix, allowing stem cells to connect and integrate with the surrounding tissue53,56. Nanoparticles can be created to transport growth hormones, genes, or other chemicals that aid in the survival and function of stem cells. Dealing with obstacles and looking ahead Potential cytotoxicity and the necessity for a more thorough comprehension of the interactions between nanomaterials and biological systems are two obstacles to using nanotechnology in stem cell research and treatment, notwithstanding the encouraging advances. These concerns are the subject of continuing research into developing safer and more effective stem cell treatment methods based on nanotechnology53. Overall, stem cell research and therapy have been significantly advanced by nanotechnology, which has provided methods and instruments that improve cell separation, differentiation, tracking, and delivery. Nanotechnology and stem cell research are working together in a way that might change the face of regenerative medicine and give people hope for various illnesses. One very encouraging treatment approach is transplanting several types of progenitor cells and stem cells to promote tissue regeneration. The availability of methods that might identify transplanted stem/progenitor cells long-term and noninvasively while monitoring their differentiation, survival, and proliferation in the target organs is critical to this strategy. Multiple photon microscopy, MRI, bioluminescence, and positron emission tomography are current methods for viewing cells in living organisms. MRI offers a number of advantages over traditional methods, such as quick processing times, good resolution, user-friendliness and the capacity to generate three-dimensional images57,58. A significant benefit of MRI is its information about the tissues around the transplanted stem cells, such as any swelling, lesions, or inflammation. These tissues can influence the transplanted stem cells’ fate or slow the healing of injured tissues59. The size-tunable magnetic iron oxide nanoparticles have enormous promise for MRI uses. When all the nuclear spins in a magnetic nanocrystal pair, it acts as a single massive magnetic domain. These moments either get trapped in one direction, making the material ferromagnetic or roam randomly, creating the material superparamagnetic at specific temperatures and crystal sizes (Fig. 3)60. Magnetic iron oxide nanoparticles crossed the blood brain barrier to deliver targeted treatment for brain diseases. More effective and targeted transport of therapeutic drugs is made possible by the unique physical and chemical characteristics of nanoparticles, which promote the delivery of drug moieties to stem cells. Nanoparticles are smaller than bigger particles, which gives them an advantage when trying to enter the inside of cells and overcome biological barriers. Because of their smaller size, molecules may be more efficiently transported into stem cells’ cytoplasm or nucleus, where they can have an impact. It is also possible to alter the surface of nanoparticles with antibodies or ligands that attach to stem cell receptors. The focused strategy improves the safety profile of the treatment by reducing off-target effects and increasing the effectiveness of molecular distribution. It ensures that the nanoparticles are more likely to engage with the designated stem cells. Nanoparticles have the added benefit of transporting and releasing nucleic acids, proteins, and medications in a regulated manner61,62. The drug-regulated release is essential for boosting the treatment’s effectiveness by maintaining therapeutic levels in the stem cells for long periods (as shown in Fig. 4). To further ensure that therapeutic molecules reach their intended target undamaged, nanoparticle encapsulation shields them from degradation that could occur in the biological milieu. To improve the transport of molecules to stem cells and increase the possible results of stem cell treatments, nanoparticles are an essential tool due to their combination of increased cellular uptake, focused distribution, controlled release, and drug preservation. Accelerated ligand-regulated magnetic nanoparticle targeted administration for precise brain therapy. The transport of stem cells and the effectiveness of regenerative treatments are improved by nanoparticle interactions with the extracellular matrix (ECM). Nanoparticles may induce stem cell survival, proliferation, and differentiation by imitating the ECM’s biochemical and structural features. Nanoparticles engineered to mimic the ECM’s physical characteristics or transport ECM components—like growth factors or stem cell-interacting proteins—are responsible for this. One example is the ability to manufacture nanoparticles with surface chemistry or topography that resembles the natural ECM. This allows for improved adherence and signalling to the stem cells. Because of this enhanced communication, stem cells are more likely to integrate well into their new host tissue after transplantation63. In addition, nanoparticles can alter the ECM, which might remove obstacles that may hinder the movement or distribution of stem cells. To better distribute stem cells throughout the tissue and allow for deeper penetration, enzyme-functionalized nanoparticles, for instance, may selectively destroy specific components of the ECM64,65. Nanoparticles may release bioactive chemicals to improve the ECM’s regeneration ability further and decrease inflammation that may impede stem cell activity. This makes the ECM more receptive to stem cell engraftment. Nanoparticles provide a milieu conducive to stem cell integration and function via these interactions, in addition to improving the physical transport of stem cells to the target site66. This multi-pronged strategy can potentially enhance the efficacy and efficiency of stem cell treatments by using nanoparticles’ unique properties to interact with and alter the ECM. The use of nanotechnology in stem cell treatment has great promise, but several obstacles must be overcome before its full potential can be realised. Nanoparticle cytotoxicity, which may change with particle size, shape, aspect ratio, and surface charge, is a significant cause for worry. The viability and functioning of stem cells may be compromised by this toxicity, which might have unintended consequences in therapeutic applications. Nanoparticles interact with the body’s intricate biological milieu, including the immune system67. This contact might cause immunological responses or the development of protein coronas, which change the behaviour and effectiveness of the nanoparticles. Another major hurdle is the need for exact control over the behaviour of nanoparticles inside the body to guarantee focused distribution and activation. Stem cell treatments are less effective and have a higher risk of adverse effects due to the lack of control that might lead to off-target consequences. In addition, comprehensive biocompatibility evaluations and long-term studies are required due to worries about chronic toxicity and environmental effects caused by nanoparticles’ stability and possible buildup in the body. Furthermore, stem cell treatments based on nanotechnology face a complicated and ever-changing regulatory environment. Due to these technologies’ unique and perhaps poorly understood nature, ensuring compliance with regulatory requirements and securing clearance may be challenging. Further complicating matters are ethical concerns, which must be addressed appropriately to develop stem cell research and its therapeutic applications. Regulatory solid frameworks that guarantee patient safety without limiting innovation and continuous research to create safer, more effective nanoparticle designs and delivery technologies are necessary to overcome these obstacles. Overcoming these obstacles and fully realising the promise of nanotechnology in stem cell treatment will need multidisciplinary cooperation as science advances. Benefits and risks of nanotechnology and stem cells in liver transplantation Though they have some possible risks that need to be carefully considered, nanotechnology and stem cell-based treatments offer great promise for enhancing liver transplantation results. Targeted drug delivery to transplanted organs, better organ preservation, better imaging and diagnostics, tissue engineering and bioengineered liver tissue are just a few of the advantages of nanotechnology. More accurately delivering immunosuppressant’s and protecting agents, nanoparticles may prolong preservation durations and lower rejection. Mesenchymal stem cells in particular are used in stem cell treatments, which have the potential to repair injured liver tissue and lessen the need for transplantation of whole organs68. Rejection may be lessened by their immunomodulatory effects. These strategies, meanwhile, are not without dangers. Concerns with stem cells include possible tumorigenicity, particularly with pluripotent stem cells, as well as the possibility of infection, emboli formation, and unintentional differentiation69. There has been liver damage seen with some inorganic nanoparticles. It is currently unclear how safe and effective stem cell treatments are over the long run. Notwithstanding these obstacles, research is still going strong; certain stem cell and nanoparticle-based liver disorder treatments are now in clinical trials. As these technologies get closer to more extensive clinical use in liver transplantation, careful assessment of the risk-benefit balance will be essential. Because pluripotent stem cells may differentiate into several cell types, one of the main worries is the possibility of tumour development. Transplanted stem cells run the danger of being rejected by the immune system even with their immunomodulatory qualities70. An additional possible problem is the unintended development of stem cells into undesirable cell types. Emboli development has been linked in certain research to specific stem cell transplantation techniques71. Like with any transplantation operation, there are also worries regarding the possibility of infection. It will need further study to completely determine the long-term safety and effectiveness of stem cell therapy for liver disorders. Hepatocyte necrosis and bleeding have been reported as serious effects of several inorganic nanoparticles used in combination with stem cell treatments72,73. These hazards emphasize how carefully patients receiving stem cell-based therapy for liver disorders must be evaluated and monitored. Addressing these safety issues and developing uniform procedures will be essential as research advances if stem cell treatments are to be used widely in liver transplantation. Clinical trials in liver transplantation and stem cell-based therapy HE associated with neurological disorders has been treated with lactulose and rifaximin till now. Among more than 20 registered clinical options such as faecal microbiota transplantation, equine anti-thymocyte globulin, nitazoxamide and a few antimicrobials are being repurposed and tested in various clinical trial studies74. Recently, a multicentric randomized controlled trial has explored the safety and efficiency of faecal microbiota transplants having various bacterial doses for treating patients with recurrent HE (NCT05669651) (Fig. 5). In another comparative clinical study, a randomized controlled trial of nitazoxanide and lactulose combination with a single lactulose dose therapy in HE subjects is currently in phase 3 (NCT05754996). Another trial reported the adjunct effect of lactoferrin in humans with HE and is in phase 2 (NCT06072521). Based on stem cell-based therapy for HE, many research outcomes are currently preclinical or nascent. In this direction, HepaStem has been developed by Promethera Biosciences, which is a liver-derived stem cell therapy in extreme liver conditions [cirrhosis, pre-cirrhotic nonalcoholic steatohepatitis (NASH) and acute-on-chronic liver failure (ACLF)]75. Moreover, faecal microbiota transplantation has some limitations related to toxic manifestations; therefore, stem cell therapy can be used as a novel alternative option for the treatment of liver damage-mediated neurological dysfunction. The efficacy and safety of faecal microbiota transplantation in the management of recurrent hepatic encephalopathy patients. Patents and intellectual property Patents play a crucial role in protecting innovations in the field of stem cell transplantation therapy for advanced liver damage-associated neurodegenerative disorders. These patents safeguard the intellectual property rights of researchers and companies, encouraging further investment in research and development. By granting exclusive rights to the inventors, patents stimulate innovation and ensure that new therapies reach the market, benefiting patients in need. Table 1 below illustrates a selection of key patents in this area, highlighting the diversity of approaches and techniques being developed to address the complex challenges of treating neuro-degenerative disorders through stem cell transplantation therapy. Table 1Key Patents on Stem Cell Transplantation therapy in damaged liverSr. No.Patent NumberCountryPatent TitleYear of publicationReference1.US-20240124518-A1USAMethods for preparing purified polypeptide compositions2024762.US-20240124839-A1USAGeneration of neural stem cells from human trophoblast stem cells2024773.CN201811065453CHINAMulti-functional liver transplant station2018784.US-5019092-AUSAA liver transplant clamp1991795.AU2024200945A1AUSTRALIARna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)2024806.US-20240122991-A1USATransplantation of liver cells by administration to the biliary tree of the liver2024817.US5061620AUSAHuman hematopoietic stem cell1991828.US-5843780-AUSAPrimate embryonic stem cells1998839.US-20240117431-A1USAStem cell-based biomarker discovery20248410.US-20240084237-A1USAStem cell-derived mature cardiomyocytes and cardiovascular disease models using the same20248511.US11795436B2USADerivation of hepatic stem cells and mature liver cell types and uses thereof20238612.US11181536B2USAMethods for monitoring treatment of chronic liver disease20218713.US20210228644A1USANeural stem cell compositions and methods to treat neurodegenerative disorders20218814.US20200199538A1USADerivation of liver organoids from human pluripotent stem cells20208915.JP2022095914AJAPANEngineered liver tissues, arrays thereof and methods of making the same20229016.CN108431209BCHINADerived and mature hepatocyte types of liver stem cells and use thereof202391 Key Patents on Stem Cell Transplantation therapy in damaged liver Conclusion HE is a common consequence of liver cirrhosis, which is a serious global health concern. There is still much to learn about the precise molecular pathways behind HE. This illness not only impairs usual functioning and productivity at work but also makes the prognosis worse for patients with advanced liver disease. Stem cell-based therapy as an alternative therapeutic option can potentially improve patient outcomes. Using nanotechnology to enhance the delivery and effectiveness of stem cell therapies can contribute significantly to tissue regeneration. The integration of ChatGPT and mRNA nanovaccines in to their liver transplantation can help in improving patient compliance92,93. This review represents a notable advancement in medical science, offering improved treatment outcomes for revolutionary medical advancements in this area, which is high for future research. Ethical approval Not applicable. Consent Not applicable. Source of funding Not applicable. Author contribution A.S.: study concept, data collection, writing original draft. A.S.: writing original draft. D.D.: writing original draft. R.R.S.: writing original draft. V.P.: supervision. S.B.: writing original draft. A.S.: writing original draft. S.M.: supervision and writing—review and editing. R.G.: writing—review and editing. Priyanka: supervision and visualization. H.C.: supervision and writing—review and editing. Conflicts of interest disclosure The authors declare no conflicts of interest. Research registration unique identifying number (UIN) Not applicable. Guarantor Hitesh Chopra. Data availability statement No new datasets generated during the study. Provenance and peer review Invited paper. Footnotes Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online 23 July 2024 Contributor Information Anjna Sharma, Email: anjna.sharma@chitkarauniversity.edu.in. Ameya Sharma, Email: ameya.sharma@chitkarauniversity.edu.in. Divya Dheer, Email: divya.dheer@chitkarauniversity.edu.in. Raghu Rai Sharma, Email: raghurai.sharma@chitkarauniversity.edu.in. Vivek Puri, Email: vivek.puri@chitkarauniversity.edu.in. Shabana Bibi, Email: shabana.bibi.stmu@gmail.com. Amina Shamas, Email: amina.shamas029@gmail.com. Sameeullah Memon, Email: Sam.memon337@gmail.com. Rajat Goyal, Email: rajatgoyal338@gmail.com. References Associated Data Data Availability Statement No new datasets generated during the study.